Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its quarterly earnings results on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the prior year, the firm earned ($0.42) EPS. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year.

Recursion Pharmaceuticals Stock Down 3.6 %

RXRX stock traded down $0.28 during midday trading on Friday, hitting $7.39. The company’s stock had a trading volume of 28,741,729 shares, compared to its average volume of 25,913,592. The company’s fifty day moving average price is $7.69 and its 200 day moving average price is $7.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $14.12. The stock has a market capitalization of $2.89 billion, a P/E ratio of -4.81 and a beta of 0.86.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.